Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sarocladium strictum ethyl acetate extract
- Development stage
- Preclinical
- Lead developer
- Florida International University
01
Overview
Sarocladium strictum ethyl acetate extract is a fungal extract derived from the secondary metabolites of the endophytic fungus Sarocladium strictum. It is currently being investigated for its potential as a malaria transmission-blocking agent [1.1]. In preclinical evaluations, the extract demonstrated the ability to completely block the transmission of the malaria parasite Plasmodium falciparum to Anopheles gambiae mosquitoes in standard membrane feeding assays (SMFA) [1.1]. Active fractions of the extract have been shown to significantly reduce the number of oocysts in mosquitoes, serving as a starting point for isolating and identifying potent antimalarial lead compounds [1.1].
Beyond the preview
Go deeper on Sarocladium strictum ethyl acetate extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sarocladium strictum ethyl acetate extract.